Synedgen uses the science of glycomics – the study of complex sugar structure and function – to discover and develop ultra-purified therapeutic polysaccharides that are soluble, active, and targeted in the human body. These new molecular entities are designed to alter the progression of diseases that currently have limited treatment options, and improve the lives of patients.
June 8, 2018
Synedgen Welcomes Student Interns
May 23, 2018
Synedgen Receives FDA 510(k) Clearance for Catasyn™ Advanced Technology Wound Hydrogel
February 15, 2018
Synedgen Expands Research Focus to broaden indications for core platform of novel pharmaceuticals — Appoints New Senior Scientist to lead research and discovery team